Skip to main content

Table 2 The combination index (CI) in uterine LMS cell lines

From: Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines

Cell Line Drugs Combination index (CI) at the IC 50
SK-UT-1   
  Gemcitabine:Docetaxel 0.59
  Gemcitabine + Docetaxel + Dasatinib 0.46
  Dasatinib- > Gemcitabine + Docetaxel 1.77
  Gemcitabine + Docetaxel- > Dasatinib 1.14
  Dasatinib + Gemcitabine- > Docetaxel 1.32
  Dasatinib + Docetaxel- > Gemcitabine 1.07
  Gemcitabine- > Docetaxel + Dasatinib 1.8
  Docetaxel- > Gemcitabine + Dasatinib N/D
SK-UT-1B   
  Gemcitabine:Docetaxel 1.36
  Gemcitabine + Docetaxel + Dasatinib 1.4
  Dasatinib- > Gemcitabine + Docetaxel 0.9
  Gemcitabine + Docetaxel- > Dasatinib 1.36
  Dasatinib + Gemcitabine- > Docetaxel 1.21
  Dasatinib + Docetaxel- > Gemcitabine 1.0
  Gemcitabine- > Docetaxel + Dasatinib 0.9
  Docetaxel- > Gemcitabine + Dasatinib 1.5
  1. Combination index scale: CI <0.9 synergistic, CI = 0.9-1.1 additive, CI = 1.1-1.2 slight antagonism,
  2. CI = 1.2-1.45 moderate antagonism, CI = 1.45-3.3 antagonism, CI = 3.3-10 strong antagonism.
  3. N/D = not determined.
Back to article page

Gynecologic Oncology Research and Practice

ISSN: 2053-6844

Contact us